TFS Capital’s Neurocrine Biosciences NBIX Stock Holding History

TFS Capital’s Portfolio NBIX Stock Details NBIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	–	Sell	-23,493	Closed	-$909K	–	784
2016 Q4	$909K	Buy	+23,493	New	+$1.06M	0.24%	149
2014 Q4	–	Sell	-24,826	Closed	-$389K	–	1095
2014 Q3	$389K	Buy	+24,826	New	+$371K	0.03%	672
2014 Q2	–	Sell	-10,131	Closed	-$163K	–	1278
2014 Q1	$163K	Buy	+10,131	New	+$173K	0.01%	1230
2013 Q3	–	Sell	-61,438	Closed	-$822K	–	1560
2013 Q2	$822K	Buy	+61,438	New	+$755K	0.03%	695

Other funds holding NBIX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

JHIU

Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

TFS Capital's NBIX Position: Q1 2017 in Review

TFS Capital sold out of Neurocrine Biosciences (NBIX) in Q1 2017, closing a stake of 23,493 shares — an estimated $909K sold.

TFS Capital first reported a position in NBIX in Q2 2013 and held it in 4 quarters. The position peaked at $909K in Q4 2016. 218 funds tracked by Wall St. Rank hold NBIX as of Q1 2017.

TFS Capital reported no remaining Neurocrine Biosciences position as of Q1 2017 after selling out during the quarter.
TFS Capital sold 23,493 Neurocrine Biosciences shares in Q1 2017, an estimated $909K.
TFS Capital first reported a position in Neurocrine Biosciences in Q2 2013 and held it in 4 quarters.
TFS Capital's Neurocrine Biosciences position peaked at $909K in Q4 2016.
218 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q1 2017.

Based on TFS Capital's 13F filing for Q1 2017, filed 5 May 2017.